Estrella Immunopharma (ESLA) announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected Artemis T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The new site, Baylor Research Institute d/b/a Baylor Scott & White Research Institute in Dallas, Texas, is now open for patient enrollment.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESLA:
- Estrella Immunopharma Expands STARLIGHT-1 Clinical Trial
- Estrella Immunopharma Raises $3.35M in Private Placement
- Estrella Immunopharma to sell 2.333M shares at $1.50 in private placement
- Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial
- Estrella Immunopharma doses first patient in second cohort of STARLIGHT-1 trial